



RECEIVED
AUG 14 2002
TECH CENTER 1600/2900

FORM 100 (Modified)				Attorney Docket No.: 020862-000110US		Application No.: 10/091,744	
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				Applicant: ANDREW HOLMAN			
				Filing Date: March 5, 2002		Group: 1614	
Reference Designation				U.S. PATENT DOCUMENTS			
Page 1 of 1							
Examiner Initial		Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)
SH	AA	4,452,808	6/5/84	Gallagher, Jr.			
	AB	4,843,086	6/27/89	Griss deceased <i>et al.</i>			
	AC	4,886,812	12/12/89	Griss deceased <i>et al.</i>			
	AD	5,112,842	5/12/92	Zierenberg, <i>et al.</i>			
	AE	5,650,420	7/22/97	Hall, <i>et al.</i>			
	AF	5,658,955	8/19/97	Hitzig			
	AG	5,694,950	12/9/97	McMichael			
	AH	5,696,128	12/9/97	Cincotta, <i>et al.</i>			
	AI	5,786,344	7/28/98	Ratain <i>et al.</i>			
	AJ	5,842,997	12/1/98	Verrier <i>et al.</i>			
	AK	5,843,943	12/1/98	Carson <i>et al.</i>			
	AL	5,872,127	2/16/99	Cincotta <i>et al.</i>			
	AM	5,872,133	2/16/99	Cincotta <i>et al.</i>			
	AN	5,905,083	5/18/99	Cincotta <i>et al.</i>			
	AO	5,921,940	7/13/99	Verrier <i>et al.</i>			
	AP	5,932,252	8/3/99	Morris Jr. <i>et al.</i>			
	AQ	5,952,389	9/14/99	Fogel			
	AR	6,001,861	12/14/99	Oertel <i>et al.</i>			
	AS	6,057,373	5/2/00	Fogel			
	AT	6,156,777	12/5/00	Hall <i>et al.</i>			
	AU	6,191,153	2/20/01	Hammer <i>et al.</i>			
	AV	6,194,445	2/27/01	Oertel <i>et al.</i>			
	AW	6,204,245	3/20/01	Siegel <i>et al.</i>			
	AX	6,255,329	7/3/01	Maj			
	AY	6,258,827	7/10/01	Chenard <i>et al.</i>			
	AZ	6,277,875	8/21/01	Holman			
SH	BA	6,294,583	9/25/01	Fogel			
	BB	6,300,365	10/9/01	Holman			
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							

Varkey

3/6/06




RECEIVED

AUG 1 4 2002

FORM PTO/JA-102 (Modified)		Attorney Docket No.: 020862-000110US	TECH CENTER 1800/2900
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: ANDREW HOLMAN	
		Filing Date: March 5, 2002	Group: 1614
SM	BC	Aksoyek <i>et al.</i> , "Assessment of autonomic nervous system function in patients with Behcet's disease by spectral analysis of heart rate variability," <i>J. Auton. Nerv. Syst.</i> 77(2-3):190-4 (Sept. 24, 1999).	
	BD	Alvarez-Nemegyei <i>et al.</i> , "Bromocriptine in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled study," <i>Lupus</i> 7(6):414-9 (1998).	
	BE	Bathon, "Rheumatoid Arthritis-treatment," Abstract from the Highlights of the 1998 American College of Rheumatology National Scientific Meetings.	
	BF	Breedveld, "New tumor necrosis factor-alpha biologic therapies for rheumatoid arthritis," <i>Eur. Cytokine Netw.</i> 9:233-38 (1998).	
	BG	British Society for Rheumatology, The Programme from the XIXth Annual General Meeting, Brighton, UK (April 23-26, 2002).	
	BH	Chokroverty and Jankovic, "Restless legs syndrome: A disease in search of identity," <i>Neurology</i> 52(5):907-10 (Mar. 23, 1999).	
	BI	Damase-Michel <i>et al.</i> , "Effects of dopaminergic drugs on the sympathoadrenal system," <i>Hypertens Res.</i> 18(1):1:S119-24 (1995).	
	BJ	Drewes, "Pain and sleep disturbances with special reference to fibromyalgia and rheumatoid arthritis," <i>Rheumatology (Oxford)</i> 38(11):1035-1038 (Nov. 1999).	
	BK	Eijsbouts <i>et al.</i> , "Treatment of rheumatoid arthritis with the dopamine agonist quinagolide," <i>J. Rheumatol.</i> 26(10):2284-5 (Oct. 1999).	
	BL	Elenkov <i>et al.</i> , "The Sympathetic Nerve - An Integrative Interface between Two Supersystems: The Brain and the Immune System," <i>Pharmacological Review</i> 52(4):595-638 (2000).	
	BM	Gao <i>et al.</i> , "Effects of dopaminergic agents on carrageenan hyperalgesia in rats," <i>Eur. J. Pharmacol.</i> 406(1): 53-8 (2000).	
	BN	Hanna <i>et al.</i> , "Switching from pergolide to pramipexole in patients with Parkinson's disease," <i>J. Neural. Transm.</i> 108:63-70 (2001).	
	BO	Hennig, "Restless Leg Syndrome: Diagnosis and Treatment," <i>Hospital Medicine</i> , pp. 54-75 (Nov. 1997).	
	BP	Holman, "Pramipexole for Fibromyalgia: Initial Observations and Rationale," Abstract: FAME meeting, Chicago, IL (Jun. 22-23, 2001).	
	BQ	Holman, "The Relationship of Sleep and Autonomic Function on Autoimmune Disease," Abstract: FAME meeting, Chicago, IL (Jun. 22-23, 2001).	
	BR	Holman, "Safety and Efficacy of Sleep of the Dopamine Agonist, Pramipexole, on Pain Score for Refractory Fibromyalgia," Arthritis and Rheumatism, Abstract for: 2000 Annual Scientific Meeting 43:9 1599 (2000).	
	BS	Honda <i>et al.</i> , "Dopamine D ₃ agonists into the substantia nigra aggravates cataplexy but do not modify sleep," <i>NeuroReport</i> 10(14): 3111-8 (Sept. 1999).	
	BT	Huynh <i>et al.</i> , The Effects of Pramipexole in a Rodent Model of Early Parkinson's Disease," Online Abstract, Short Term Training Program, Department of Neurology, School of Medicine, UCLA, Los Angeles, CA (Summer 2001).	
	BU	Lagos <i>et al.</i> , "Effects of the D ₃ preferring dopamine agonist pramipexole on sleep and waking, locomotor activity and striatal dopamine release in rats," <i>Eur. Neuropsychopharmacol.</i> 8(2):113-20 (May 1998).	
	BV	Lam, "Clinical pharmacology of dopamine agonists," <i>Pharmacotherapy</i> 20(1 Pt. 2): 17S-25S (2000).	
	BW	Leanos Miranda <i>et al.</i> , "Prolactin as an immunomodulator," <i>Rev. Alerg. Mex.</i> 44(5):116-23 (Sept-Oct., 1997).	
	BX	Lechin <i>et al.</i> , "Plasma neurotransmitters and cortisol in chronic illness: role of stress," <i>J. Med.</i> 25(3-4): 181-92 (1994).	
SH	BY	Lieberman, "Management of Patients With Newly Diagnosed PD," Published in <i>Young Parkinson's Handbook</i> , Chapter 3: The Medical Management of PD, http://spauldingrehab.mgh.harvard.edu (printed Nov. 19, 2001).	

Sanchez 3/6/06



RECEIVED

AUG 1 4 2002

FORM PTO-1449 (Modified)		Attorney Docket No.: 020862-000110US	TECH CENTER 1600/2900
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: ANDREW HOLMAN	
		Filing Date: March 5, 2002	Group: 1614
571	BZ	Lin <i>et al.</i> , "Effect of pramipexole in treatment of resistant restless legs syndrome," <i>Mayo Clin. Proc.</i> 73(6):497-500 (Jun. 1998).	
	CA	Lorenc-Koci and Wolfarth, "Efficacy of pramipexole, a new dopamine receptor agonist, to relieve the Parkinsonian-like muscle rigidity in rats," <i>Eur. J. Pharmacol.</i> 385(1):39-46 (1999).	
	CB	Luchsinger <i>et al.</i> , "Comparative effects of dopaminergic agonists on cardiovascular, renal, and renin-angiotensin systems in hypertensive patients," <i>J. Clin. Pharmacol.</i> 32(1):55-60 (1992).	
	CC	Mader, "Bromocriptine for refractory rheumatoid arthritis," <i>Harefuah</i> 133(11):527-9, 591 (Dec. 1, 1997).	
	CD	Maj <i>et al.</i> , "Antidepressant effects of pramipexole, a novel dopamine receptor agonist," <i>J. Neural. Transm.</i> 104: 4-5, 525-33 (1997).	
	CE	Maj <i>et al.</i> , "The effect of repeated treatment with pramipexole on the central dopamine D ₃ system," <i>J. Neural. Transm.</i> 107(12): 1369-79 (2000).	
	CF	Mannelli <i>et al.</i> , "In Vivo Evidence That Endogenous Dopamine Modulates Sympathetic Activity in Man," <i>Hypertension</i> 34:398-402 (1999).	
	CG	Mannelli <i>et al.</i> , "Dopamine and sympathoadrenal activity in man," <i>Clin. Exp. Hypertens.</i> 19(1-2):163-79 (1997).	
	CH	Martinez-Lavin <i>et al.</i> , "Circadian studies of autonomic nervous balance in patients with fibromyalgia," <i>Arthritis & Rheumatism</i> 41:1966-71 (Nov. 1998).	
	CI	Mehta <i>et al.</i> , "Heart rate variability in healthy newborn infants," <i>Am. J. Cardiol.</i> 89(1):50-3 (Jan. 1, 2002).	
	CJ	Mohler <i>et al.</i> , "Pramipexole in the treatment of advanced Parkinson's disease," <i>Eur. J. Neurology Suppl.</i> (Suppl. 1):21-25 (2000).	
	CK	Mohler <i>et al.</i> , "Soluble Tumor Necrosis Factor (TNF) Receptors Are Effective Therapeutic Agents in Lethal Endotoxemia and Function Simultaneously as Both TNF Carriers and TNF Antagonists," <i>J. Immunol.</i> 151:1548-1561 (Aug. 1, 1993).	
	CL	Monti and Monti, "Role of dorsal raphe nucleus serotonin 5-HT _{1A} receptor in the regulation of REM sleep," <i>Life Sci.</i> 66(21):1999-2012 (2000).	
	CM	Montplaisir <i>et al.</i> , "Restless legs syndrome improved by pramipexole: a double-blind randomized trial," <i>Neurology</i> 52(5):938-43 (1999).	
	CN	Montplaisir <i>et al.</i> , "Pramipexole in the treatment of restless legs syndrome: a follow-up study," <i>Eur. J. Neurol.</i> 7 Suppl. 1:27-31 (May 2000).	
	CO	Orr <i>et al.</i> , "Autonomic regulation of cardiac function during sleep in patients with irritable bowel syndrome," <i>Am. J. Gastroenterol.</i> 95(10): 2865-71 (2000).	
	CP	Penzel <i>et al.</i> , "Heart rate variability during sleep stages in normals and in patients with sleep apnea," <i>Stud. Health Technol. Inform.</i> 77:1256-60 (2000).	
	CQ	Prescott (ed.), "Lipid Vesicles as Carriers for Introducing Biologically Active Materials into Cells," <i>Methods in Cell Biology</i> , Volume XIV, Ch. 4, Academic Press, New York, N.Y. (1976).	
	CR	Quinn <i>et al.</i> , "Painful Parkinson's Disease," <i>Lancet</i> 1(8494):1366-9 (Jun. 14, 1986).	
	CS	Renzetti and Gater, "Ro 45-2081, a TNF receptor fusion protein, prevents inflammatory responses in the airways," <i>Inflamm. Res.</i> 46(2):S143-S144 (1997).	
	CT	Schilling <i>et al.</i> , "Neuroendocrine and side effect profile of pramipexole, a new dopamine receptor agonist, in humans," <i>Clin. Pharmacol. Ther.</i> 51(5):541-8 (May 1992).	
	CU	Sears, "The evolution of β_2 -agonists," <i>Respir. Med.</i> 95(B): S2-6 (Aug. 2001).	
54	CV	Silber, "Concise review for Primary-Care Physicians: Restless legs syndrome," <i>Mayo Clin. Proc.</i> 72(3):261-4 (Mar. 1997).	

Sarkis 3/6/06




RECEIVED

AUG 1 4 2002

TECH CENTER 1600/2900

FORM PTO-1449 (Modified)		Attorney Docket No.: 020862-000110US	Application No.: 10/091,744
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: ANDREW HOLMAN	
		Filing Date: March 5, 2002	Group: 1614
82	CW	Sinoway, "Direct Assessment of Sympathetic Neural Activity in Patients with Heart Failure During Exercise," Abstract from Research Workshop entitled "Effect of Acupuncture on Cardiovascular Disease, Its Mechanism and Clinical Application", University of California at Irvine (Oct. 14-15, 2000).	
	CX	Sjolin and Trykker, "Unsuccessful treatment of severe pain from bone metastasis with Sinemet 25/100," <i>N. Engl. J. Med.</i> 312(10):650-1 (Mar. 7, 1985).	
	CY	Sun <i>et al.</i> , "Iron and the restless legs syndrome," <i>Sleep</i> 21(4):371-7 (1998).	
	CZ	Trenkwalder <i>et al.</i> , "Periodic limb movements and restless legs syndrome," <i>Neurol. Clin.</i> 14(3):629-50 (Aug. 1996).	
	DA	Tsuru <i>et al.</i> , Forum Minireview - Pharmacology and Physiology of Perivascular Nerves Regulating Vascular Function: "Role of perivascular sympathetic nerves and regional differences in the features of sympathetic innervation of the vascular system," <i>Jpn. J. Pharmacol.</i> 88(1):9-13 (2002).	
	DB	Velasco and Luchsinger, "Dopamine: pharmacologic and therapeutic aspects," <i>Am. J. Ther.</i> 5(1):37-43 (1998).	
	DC	Weimerskirch and Ernst, "Newer dopamine agonists in the treatment of restless legs syndrome," <i>Ann. Pharmacother.</i> 35:627-30 (May 2001).	
	DD	Winkelman <i>et al.</i> , "Restless legs syndrome in end-stage renal disease," <i>Am J. Kidney Dis.</i> 28(3):372-378 (Sept. 1996).	
	DE	Wolfe <i>et al.</i> , "The American College of Rheumatology 1990 - Criteria for the classification of the fibromyalgia, Report of the Multicenter Criteria Committee," <i>Arthritis and Rheumatism</i> 33(2):160-72 (Feb. 1990).	
	DF	Yan and Zhang, "Analysis of heart rate variability and its application," <i>Space Med. Med. Eng.</i> 10(5):318-22 (Oct. 1997).	
	DG	Zhang <i>et al.</i> , "Change in heart rate dynamics after aerobic training detected by approximate entropy and its association with orthostasis," <i>J. Gravit. Physiol.</i> 4(2):P-47 - P-48 (Jul. 1997).	
	DH	The Merck Index (Twelfth Edition), p. 301, No. 1889, Carisoprodol (1996).	
	DI	The Merck Index (Twelfth Edition), p. 404, No. 2449, Clonazepam (1996).	
	DJ	The Merck Index (Twelfth Edition), p. 733, No. 4343, Gabapentin (1996).	
	DK	The Merck Index (Twelfth Edition), p. 953, No. 5609, Lorazepam (1996).	
	DL	The Merck Index (Twelfth Edition), p. 991, No. 5857, Melatonin (1996).	
	DM	The Merck Index (Twelfth Edition), p. 1232, No. 7304, Pergolide (1996).	
	DN	The Merck Index (Twelfth Edition), p. 1321, No. 7885, Pramipexole (1996).	
	DO	The Merck Index (Twelfth Edition), p. 1421, No. 8416, Ropinirole (1996).	
	DP	The Merck Index (Twelfth Edition), p. 1618, No. 9624, Tizanidine (1996).	
	DQ	The Merck Index (Twelfth Edition), p. 1634, No. 9712, Trazodone (1996).	
	DR	Enbrel (etanercept), issued 01/2001 - Internet website: Immunex.	
	DS	Ambien (Zolpidem Tartrate) - "What time is it? It's time to say "Good Night" - Internet website: http://www.ambien.com (printed Mar. 5, 2001).	
	DT	Heart rate and blood pressure variability - Internet website: http://www.nymc.edu (printed Feb. 26, 2002).	
	DU	Remicade - Drug Database - Internet website: http://pharminfo.com (printed Feb. 24, 2001).	
	DV	Sonata Zalepln capsules, Clinical overview - Internet website: http://www.sonatasleep.com (printed Mar. 5, 2001).	
	DW	Searle Ambien (zolpidem tartrate) - Internet website: http://www.searlehealthnet.com (printed Mar. 5, 2001).	
81	DX	Healthcare Professionals, Introduction - "Eat Less - The point of change program encourages your patients to do more" - Internet website: http://www.4meridia.com (printed Mar. 5, 2001).	

3/6/06



RECEIVED

AUG 1 4 2002

TECH CENTER 1600/2900

FOR PPTO-1449 (Modified)		Attorney Docket No.: 020862-000110US	Application No.: 10/091,744
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: ANDREW HOLMAN	
		Filing Date: March 5, 2002	Group: 1614
SM	DY	Healthcare Professionals, Mechanism of Action- "Lose weight by eating less"- Internet website: http://www.4meridia.com (printed Mar. 5, 2001).	
EXAMINER <i>[Signature]</i>		DATE CONSIDERED 3/6/06	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

